International Clinical Psychopharmacology最新文献_第7页

Elevated liver transaminases among patients with psychiatric disorders. 精神疾病患者肝转氨酶升高。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2024-03-25 DOI: 10.1097/YIC.0000000000000514

Eman Ali, Mona Ahmed Abdel Maksoud, Shaymaa M Arafa, Doaa Ibrahim, Ahmed El-Sayed Hassan, Omnia Awwad, Ahmed M Elbeltagy, Essam Elmahdi, Reham Elgarhi, Ahmed Embaby

{"title":"Elevated liver transaminases among patients with psychiatric disorders.","authors":"Eman Ali, Mona Ahmed Abdel Maksoud, Shaymaa M Arafa, Doaa Ibrahim, Ahmed El-Sayed Hassan, Omnia Awwad, Ahmed M Elbeltagy, Essam Elmahdi, Reham Elgarhi, Ahmed Embaby","doi":"10.1097/YIC.0000000000000514","DOIUrl":"10.1097/YIC.0000000000000514","url":null,"abstract":"Hepatocyte injury is assessed by serum aspartate transaminase and alanine transaminase estimation. In psychiatric populations, antipsychotic drugs (AD) are culprit in hepatic dysfunction. To assess transaminitis among psychiatric patients treated by AD. This cross-sectional study was conducted in Zagazig University Hospitals in Egypt, from December 2022 to February 2023. A total of 135 adult patients aged ≥ 18 years, were diagnosed with psychiatric disorders after exclusion of patients receiving any hepatotoxic drugs, viral hepatitis, having chronic liver or kidney diseases, diabetes mellitus, mental retardation, and pregnant females. Among the 135 patients, 104 (77.0%) were males. Their age was 32 ± 9, The most popular used class of AD was atypical AD 84 (62.2%). The overall incidence of transaminitis among patients receiving AD was 23/135 (17.04%) of patients; 13 (56.5%) were on atypical AD compared to 10 (43.5%) patients receiving combined AD, without any statistically significant difference. The use of AD in patients with psychiatric disorders is potentially safe with minimal transaminitis (<one-fold elevation). However, baseline and regular monitoring of serum aminotransferase is recommended during treatment.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"195-200"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41138180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative efficacy of various pharmacologic treatments for alcohol withdrawal syndrome: a systematic review and network meta-analysis. 酒精戒断综合征各种药物治疗的疗效比较：系统综述和网络荟萃分析。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2023-12-27 DOI: 10.1097/YIC.0000000000000526

Li Qu, Xue-Ping Ma, Alimujiang Simayi, Xiao-Li Wang, Gui-Ping Xu

{"title":"Comparative efficacy of various pharmacologic treatments for alcohol withdrawal syndrome: a systematic review and network meta-analysis.","authors":"Li Qu, Xue-Ping Ma, Alimujiang Simayi, Xiao-Li Wang, Gui-Ping Xu","doi":"10.1097/YIC.0000000000000526","DOIUrl":"10.1097/YIC.0000000000000526","url":null,"abstract":"This study was to compare multiple classes of medications and medication combinations to find alternatives or additives for patients not applicable to benzodiazepines (BZDs). We performed a network meta-analysis to assess the comparative effect of 11 pharmacologic treatments in patients with alcohol withdrawal syndrome. Forty-one studies were included, comprising a total sample size of 4187 participants. The pooled results from the randomized controlled trials showed that there was no significant difference in the Clinical Institute Withdrawal Assessment-Alcohol, revised (CIWA-Ar) reduction with other medications or medication combinations compared to BZDs. Compared to BZDs, the mean difference in ICU length of stay of anticonvulsants + BZDs was -1.71 days (95% CI = -2.82, -0.59). Efficacy rankings from cohort studies showed that anticonvulsant + BZDs were superior to other treatments in reducing CIWA-Ar scores and reducing the length of stay in the ICU. Synthesis results from randomized controlled trials indicate that there are currently no data suggesting that other medications or medication combinations can fully replace BZDs. However, synthetic results from observational studies have shown that BZDs are effective in the context of adjuvant anticonvulsant therapy, particularly with early use of gabapentin in combination with BZDs in the treatment of alcohol withdrawal syndrome, which represents a promising treatment option.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"148-162"},"PeriodicalIF":2.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of obsessive-compulsive symptoms and their psychosocial correlates among medical students during COVID-19 pandemic. 在 COVID-19 大流行期间，医科学生中强迫症状的流行率及其社会心理相关性。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2023-08-09 DOI: 10.1097/YIC.0000000000000476

Mahsa Nahidi, Zahra Mirza Hoseinzadeh Moghaddam, Hamed Tabesh, Lahya Afshari Saleh, Farahnaz Rohani, Sheikh Shoib

{"title":"Prevalence of obsessive-compulsive symptoms and their psychosocial correlates among medical students during COVID-19 pandemic.","authors":"Mahsa Nahidi, Zahra Mirza Hoseinzadeh Moghaddam, Hamed Tabesh, Lahya Afshari Saleh, Farahnaz Rohani, Sheikh Shoib","doi":"10.1097/YIC.0000000000000476","DOIUrl":"10.1097/YIC.0000000000000476","url":null,"abstract":"This study aimed to assess the prevalence of obsessive-compulsive symptoms (OCS) among medical students during COVID-19 pandemic and to evaluate their association with related sociodemographic features and other psychological symptoms. In this cross-sectional study, students from Mashhad University of Medical Sciences with no major exam in the preceding or following month were surveyed during April to August 2021 through stratified available sampling. Data were collected by a structured online questionnaire distributed through social media platforms. OCS were assessed using Obsessive-Compulsive Inventory-Revised (OCI-R) and COVID-related stress was evaluated using COVID Stress Scale (CSS). Overall, 347 students with a mean age of 22.67 ± 2.56 years were included in this study, of whom 30.3% had probable obsessive-compulsive disorder (OCD; OCI-R score ≥21). Mean CSS scores in students with and without probable OCD were 38.64 ± 19.82 and 26.72 ± 16.63, respectively ( P < 0.005). Total CSS score was significantly correlated with OCI-R score ( r = 0.38, P = 0.001). Around one-third of the medical students reported significant OCS during COVID-19 pandemic, which was associated with higher COVID-19-related stress. Further research provides insight into management of OCD and related disorders during the COVID-19 pandemic.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"174-180"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9966654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stroke, COVID-19, and other somatic aspects of psychiatric disorders treatments. 中风、COVID-19 和其他精神疾病的躯体治疗。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2024-03-25 DOI: 10.1097/YIC.0000000000000547

Alessandro Serretti

引用次数: 0

Lurasidone as add-on to fluoxetine in obsessive-compulsive disorder with comorbid restrictive anorexia: a case report. 鲁拉西酮作为氟西汀的附加治疗药物用于伴有限制性厌食症的强迫症：病例报告。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2023-08-09 DOI: 10.1097/YIC.0000000000000502

Laura Orsolini, Silvia Bellagamba, Umberto Volpe

{"title":"Lurasidone as add-on to fluoxetine in obsessive-compulsive disorder with comorbid restrictive anorexia: a case report.","authors":"Laura Orsolini, Silvia Bellagamba, Umberto Volpe","doi":"10.1097/YIC.0000000000000502","DOIUrl":"10.1097/YIC.0000000000000502","url":null,"abstract":"Obsessive-compulsive disorder (OCD) is a pervasive disabling disorder that may overlap with other psychiatric conditions, including anorexia nervosa. Recent guidelines recommend low doses of second-generation antipsychotics as add-on therapy to selective serotonin reuptake inhibitors (SSRIs) for those patients presenting OCD who display residual symptomatology. Here we report a clinical case of a 45-years-old woman affected by severe OCD in comorbidity with anorexia nervosa, restrictive type (AN-r), treated with fluoxetine (titrated up to 40 mg/day) in augmentation with low doses of lurasidone (37 mg/day). At baseline and during a 6 months-follow-up we administered Clinical Global Impression-Severity, Symptom Checklist-90 items, Y-BOCS-II (Yale-Brown Obsessive Compulsive Scale) and EDI-3 (Eating Disorder Inventory). After 1 month of augmentation treatment, a clinically significant response was observed on obsessive symptoms at Y-BOCS-II (≥35% Y-BOCS reduction) and eating symptomatology at EDI-3. Full remission was reported after 3 months (Y-BOCS scoring ≤14) ( P < 0.01). Further longitudinal and real-world effectiveness studies should be implemented to confirm these novel results, to investigate the potential of lurasidone as add-on strategy to SSRI in poor responder OCD patients, including treatment-resistant-OCD (tr-OCD), as well as in improving eating disorder symptomatology, whereas there is comorbidity with AN-r.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"211-214"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10965133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9966656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mental health in patients affected by atopic dermatitis: which effects of treatment with dupilumab? 特应性皮炎患者的心理健康：杜匹单抗治疗有哪些效果？

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2023-12-22 DOI: 10.1097/YIC.0000000000000511

Silvia Mariel Ferrucci, Simona Tavecchio, Gregorio Nicolini, Luisa Angileri, Alessandro Ceresa, Giulia Del Tordello, Emilio Berti, Angelo Valerio Marzano, Massimiliano Buoli

{"title":"Mental health in patients affected by atopic dermatitis: which effects of treatment with dupilumab?","authors":"Silvia Mariel Ferrucci, Simona Tavecchio, Gregorio Nicolini, Luisa Angileri, Alessandro Ceresa, Giulia Del Tordello, Emilio Berti, Angelo Valerio Marzano, Massimiliano Buoli","doi":"10.1097/YIC.0000000000000511","DOIUrl":"10.1097/YIC.0000000000000511","url":null,"abstract":"Atopic dermatitis (AD) is an inflammatory skin disease. Patients with AD are prone to develop anxiety and mood disorders. Aim of this study is to investigate if treatment with dupilumab may improve mental health status of patients affected by AD. A total of 66 patients with severe AD were included: 24 subjects were candidate or have just started (one month) treatment with dupilumab, and 42 have been in treatment for one year. 25.8%, 30.3%, and 45.5% of the total sample showed, respectively, clinically significant anxiety, depression, and symptoms of Internet addiction. Patients with anxiety symptoms resulted to have more severe AD, more sleep problems ( P = 0.028), less quality of life ( P = 0.001), more severe depressive symptoms ( P < 0.001), to be more frequently women ( P = 0.016), to be less frequently treated with dupilumab for one year ( P = 0.025). Similarly, patients with clinically significant depressive symptoms resulted to have more severe AD, more sleep problems ( P = 0.003), less quality of life ( P < 0.001), more severe anxiety symptoms ( P < 0.001), to be less frequently treated with dupilumab for one year ( P = 0.008). Patients with AD treated for one year with dupilumab showed a better mental health profile in terms of less severe anxiety and depression with respect to their counterparts.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"201-205"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10965125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41178724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Change in absolute neutrophil count after COVID-19 infection in patients using clozapine versus other antipsychotics. 使用氯氮平与其他抗精神病药物的患者感染 COVID-19 后中性粒细胞绝对计数的变化。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2024-01-22 DOI: 10.1097/YIC.0000000000000506

Seong Hoon Jeong, Mi Gyung Lee, Yong Sik Kim, In Won Chung

{"title":"Change in absolute neutrophil count after COVID-19 infection in patients using clozapine versus other antipsychotics.","authors":"Seong Hoon Jeong, Mi Gyung Lee, Yong Sik Kim, In Won Chung","doi":"10.1097/YIC.0000000000000506","DOIUrl":"10.1097/YIC.0000000000000506","url":null,"abstract":"It was reported that patients who contracted COVID-19 while taking clozapine exhibited a distinct hematological response. However, the absence of control groups made it difficult to attribute it to clozapine. The changes in absolute neutrophil counts (ANCs) during the 4 weeks after COVID-19 infection were compared between the two groups of patients with severe mental illnesses (SMIs) (49 patients using clozapine and 54 using other antipsychotics) using generalized additive modeling. Although the pattern of a transient drop in ANC followed by gradual recovery could be demonstrated in both groups, it was more pronounced in the clozapine group ( P = 0.00025). Nevertheless, overall ANC remained at a higher level in the clozapine group. The results suggested potential interaction between clozapine and COVID-19 at the level of hematological dynamics. However, it did not necessarily indicate that such interaction is inevitably harmful or dangerous. It was more of a concern that some patients using other antipsychotics exhibited decreased ANC, which did not easily recover. Traditionally, clinicians have been concerned about the worsening of hematological side effects in clozapine patients after COVID-19 infection. However, the obtained result highlighted the necessity of hematological monitoring in patients using any type of antipsychotics for SMIs.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"187-194"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139541995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comprehensive overview of post-stroke depression treatment options. 全面概述中风后抑郁治疗方案。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2023-12-27 DOI: 10.1097/YIC.0000000000000532

Alberto Raggi, Alessandro Serretti, Raffaele Ferri

引用次数: 0

Sex-controlled differences in sertraline and citalopram efficacies in major depressive disorder: a randomized, double-blind trial. 舍曲林和西酞普兰对重度抑郁症疗效的性别差异：随机双盲试验。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-04-18 DOI: 10.1097/yic.0000000000000550

Ahmad Shamabadi, Hanie Karimi, Mohammad Ali Fallahzadeh, Salar Vaseghi, Razman Arabzadeh Bahri, Bita Fallahpour, Amir Hossein Abdolghaffari, Shahin Akhondzadeh

{"title":"Sex-controlled differences in sertraline and citalopram efficacies in major depressive disorder: a randomized, double-blind trial.","authors":"Ahmad Shamabadi, Hanie Karimi, Mohammad Ali Fallahzadeh, Salar Vaseghi, Razman Arabzadeh Bahri, Bita Fallahpour, Amir Hossein Abdolghaffari, Shahin Akhondzadeh","doi":"10.1097/yic.0000000000000550","DOIUrl":"https://doi.org/10.1097/yic.0000000000000550","url":null,"abstract":"To investigate the response to antidepressants while controlling for sex, which has been controversial, 92 outpatient males and females with major depressive disorder were assigned to sertraline (100 mg/day) or citalopram (40 mg/day) in two strata and were assessed using Hamilton depression rating scale (HDRS) scores and brain-derived neurotrophic factor (BDNF), interleukin (IL)-6 and cortisol serum levels in this 8-week, randomized, parallel-group, double-blind clinical trial. Data of 40 sertraline and 40 citalopram recipients with equal representation of males and females assigned to each medication were analyzed, while their baseline characteristics were not statistically different (P > 0.05). There were no significant differences between sertraline and citalopram recipients in outcome changes (P > 0.05), all of which indicated improvement, but a significant time-treatment-sex interaction effect in BDNF levels was observed (P = 0.035). Regarding this, subgroup analyses illustrated a significantly greater increase in male BDNF levels following sertraline treatment (P = 0.020) with a moderate to large effect size (Cohen's d = 0.76 and ). Significant associations were observed between percentage changes in IL-6 levels and BDNF levels in sertraline recipients (P = 0.033) and HDRS scores in citalopram recipients (P < 0.001). Sex was an effect modifier in BDNF alterations following sertraline and citalopram administration. Further large-scale, high-quality, long-term studies are recommended.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"50 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140623868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differential effects of sertraline and cognitive behavioural therapy on behavioural inhibition in patients with obsessive compulsive disorder. 舍曲林和认知行为疗法对强迫症患者行为抑制的不同影响。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-04-02 DOI: 10.1097/yic.0000000000000548

Jemma E Reid, Luca Pellegrini, Lynne Drummond, Yana Varlakova, Sonia Shahper, David S Baldwin, Christopher Manson, Samuel R Chamberlain, Trevor W Robbins, David Wellsted, Naomi A Fineberg

{"title":"Differential effects of sertraline and cognitive behavioural therapy on behavioural inhibition in patients with obsessive compulsive disorder.","authors":"Jemma E Reid, Luca Pellegrini, Lynne Drummond, Yana Varlakova, Sonia Shahper, David S Baldwin, Christopher Manson, Samuel R Chamberlain, Trevor W Robbins, David Wellsted, Naomi A Fineberg","doi":"10.1097/yic.0000000000000548","DOIUrl":"https://doi.org/10.1097/yic.0000000000000548","url":null,"abstract":"Patients with obsessive compulsive disorder (OCD) randomised to sertraline, manualised cognitive behavioural therapy (CBT), or combination (sertraline + CBT), underwent cognitive assessment. Cognitive testing was conducted at baseline and at week 16. The stop signal reaction time task (SSRT) was used to evaluate motor impulsivity and attentional flexibility was evaluated using the intra/extra-dimensional set shifting task. Paired-samples t-tests or nonparametric variants were used to compare baseline and posttreatment scores within each treatment group. Forty-five patients were tested at baseline (sertraline n = 14; CBT n = 14; sertraline + CBT n = 17) and 23 patients at week 16 (sertraline n = 6; CBT n = 7; sertraline + CBT n = 10). The mean dosage of sertraline was numerically higher in those taking sertraline as a monotherapy (166.67 mg) compared with those taking sertraline in combination with CBT (100 mg). Analysis of pre-post treatment scores using an intent-to-treat-analysis found a significant reduction in the SSRT in those treated with sertraline, whilst there was no significant change on this task for those treated with CBT or the combination. This study found that motor inhibition improved significantly following sertraline monotherapy. Suboptimal sertraline dosing might explain the failure to detect an effect on motor inhibition in the group receiving combination of sertraline + CBT. Higher dose sertraline may have broader cognitive effects than CBT for OCD, motor impulsivity may have value as a measure of treatment outcome and, by extension, the SSRT could serve as a biomarker for personalising care.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"87 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140578712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0